This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Non-invasive Intracranial Pressure Measurement Device Used To Assess Elevated Brain Pressure In Patients May Also Benefit Astronauts

BOSTON , Dec. 18, 2013 /PRNewswire/ -- A clinical research study of a non-invasive intracranial pressure measurement device has been launched by the National Space Biomedical Research Institute (NSBRI) and Vittamed Corporation, the developer of the device. The study will include the monitoring of neurological patients, as a prelude to possible future use with astronauts.

Some astronauts are developing serious visual impairment conditions with associated symptoms suggestive of elevated pressure on the brain, or increased intracranial pressure (ICP). NSBRI, a non-profit entity funded by NASA, has partnered with Vittamed Corporation to independently evaluate their proprietary Vittamed 205 device that can non-invasively measure absolute ICP without the need of patient-specific calibration. "We believe that the Vittamed device holds great promise as a reliable method to non-invasively assess intracranial pressure in astronauts as well as in patients that require monitoring on Earth," said Dr. Dorit Donoviel, NSBRI's Deputy Chief Scientist and Industry Forum Lead.

NSBRI is sponsoring the clinical validation and operational evaluation study, led by Dr. Eric Bershad, a neuro-intensivist and vascular neurologist at Baylor College of Medicine and St. Luke's Medical Center in Houston. "Currently, the only reliable way to monitor the ICP is place a catheter into the brain or cerebrospinal fluid space.  Therefore, there is an urgent need to develop non-invasive devices for measuring this important indicator of brain health," said Dr. Bershad.

The Vittamed device was selected by NSBRI after a worldwide search for the most advanced non-invasive ICP technologies. "This is a very important step for Vittamed and we are pleased that NSBRI decided to move forward with a clinical research study of our innovative device," said Vittamed's CEO, Remis Bistras.

The study was initiated in September of 2013 and is due to complete in mid-2014. Vittamed Corporation is providing equipment, training, and expert technical advice. ICP measurements obtained using the Vittamed 205 device are being compared with simultaneous lumbar puncture readings, which are considered the "gold-standard" in patients undergoing evaluation for medical reasons. A total of 40 patients will participate in the study. The Houston team is also evaluating the device for its suitability in assessing the astronauts ICP in the space environment.

The revolutionary technology was initially developed to target patients suffering from traumatic brain injuries, concussions, neurological diseases, hydrocephalus and other complications. "We are thrilled that our technology will help not only clinical patients, but also astronauts, and therefore aid the advancement of space research," said Arminas Ragauskas, Vittamed's Chief Technology Officer, Professor at Kaunas University of Technology, and inventor of the technology.

About Vittamed Corporation

Vittamed is a Boston-based medical device company with research and development operations in Lithuania. It has developed a suite of revolutionary clinically proven devices: non-invasive intracranial pressure (ICP) meter and non-invasive real-time Cerebral Autoregulation monitoring device.  The patented advanced technology of the Vittamed 205 device uses ultrasound technology to measure absolute ICP levels and does not require patient specific calibration.  So far, multiple clinical trials with several hundred traumatic brain injury, neurological and other patients have proven that Vittamed device delivers reliable, clinically acceptable, accurate and precise results as compared to today's standard of care invasive intraventricular and lumbar puncture "gold standard" ICP measurements.

Currently, Vittamed is preparing for regulatory CE mark and 510(k) filings and future commercialization of the devices. For more information, please visit www.vittamed.com.

About NSBRI

NSBRI, is a 501(c)3 organization funded by NASA. Its mission is to lead a national program to mitigate the health risks related to human spaceflight and to apply the discoveries to improve life on Earth. Annually, the Institute's science, technology and education projects take place at approximately 60 institutions and companies across the United States. For more information, please visit www.nsbri.org.

Contacts: Remis BistrasPresident & CEOVittamed Corporation rbistras@vittamed.com978-254-5160

Ron GilmoreDirector of Science and Education CommunicationsNational Space Biomedical Research Institute (NSBRI) Ronald.gilmore@bcm.edu713-798-7595

SOURCE Vittamed Corporation

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs